4-[2-(4-{(E)-3-[(S)-2-hydroxy-1-(methyl)ethylcarbamoyl]prop-1-enyl}phenyl)ethyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-[2-(4-{(E)-3-[(S)-2-hydroxy-1-(methyl)ethylcarbamoyl]prop-1-enyl}phenyl)ethyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridine
• 英文别名: 4-[2-(4-((E)-3-[(S)-2-hydroxy-1-(methyl)ethylcarbamoyl]prop-1-enyl)phenyl)ethyl]-3-(2,3,4,6-tetra-O-pivaloyl-beta-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridine；[(2R,3R,4S,5R,6S)-3,4,5-tris(2,2-dimethylpropanoyloxy)-6-[[4-[2-[4-[(E)-4-[[(2S)-1-hydroxypropan-2-yl]amino]-4-oxobut-1-enyl]phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]oxy]oxan-2-yl]methyl 2,2-dimethylpropanoate
• 化学式: C₄₇H₆₆N₄O₁₂
• 分子量: 879.061
• InChiKey: JAPABDBJQNKCGL-MLNDKQLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  63
• 可旋转键数：
  23
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  215
• 氢给体数：
  3
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  4-[2-(4-{(E)-3-[(S)-2-hydroxy-1-(methyl)ethylcarbamoyl]prop-1-enyl}phenyl)ethyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridine 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 4-[2-(4-(3-[(S)-2-hydroxy-1-(methyl)-ethylcarbamoyl]propyl)phenyl)ethyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridine
  参考文献：
  名称：

  EP1724278

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(2-{4-[(E)-3-Carboxyprop-1-enyl]phenyl}ethyl)-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]-pyridine 、 L-氨基丙醇 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-[2-(4-{(E)-3-[(S)-2-hydroxy-1-(methyl)ethylcarbamoyl]prop-1-enyl}phenyl)ethyl]-3-(2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosyloxy)-1H-pyrazolo[3,4-b]pyridine
  参考文献：
  名称：

  EP1724278

  摘要：

  公开号：

文献信息

• NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS
  申请人：FUSHIMI Nobuhiko

  公开号：US20080188426A1

  公开（公告）日：2008-08-07

  The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula R 1 represent H, an optionally substituted alkyl group, an alkenyl group, etc.; R 2 represent H, a halogen atom or an alkyl group; R 3 and R 4 represent H, OH, a halogen atom, an optionally substituted alkyl group, etc.; Y represents CH or N; Q represents alkylene, alkenylene, etc.; ring A represents an aryl group or a heteroaryl group; G represents a group represented by the following general formula (G-1) or (G-2) (in which E 1 represents H, F or OH; and E 2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

  本发明提供以下通式所表示的含氮融合环衍生物，或其药学上可接受的盐或前药，它们在人类SGLT中表现出优异的抑制活性，并可用作预防或治疗与高血糖相关的疾病，如糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症或肥胖症的药物。其中，通式中R1代表H，可选取代的烷基，烯基等；R2代表H，卤素原子或烷基；R3和R4代表H，OH，卤素原子，可选取代的烷基等；Y代表CH或N；Q代表烷基，烯基等；环A代表芳基或杂芳基；G代表下列通式（G-1）或（G-2）所表示的基团（其中E1代表H，F或OH；E2代表H，F，甲基基团等），以及包含它们的制药组合物和制药用途。
• Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
  申请人：Fushimi Nobuhiko

  公开号：US20070191289A1

  公开（公告）日：2007-08-16

  The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula R 1 represent H, an optionally substituted alkyl group, analkenyl group, etc.; R 2 represent H, a halogen atom or an alkyl group; R 3 and R 4 represent H, OH, a halogen atom, an optionally substituted alkyl group, etc.; Y represents CH or N; Q represents alkylene, alkenylene, etc.; ring A represents an aryl group or a heteroaryl group; G represents a group represented by the following general formula (G-1) or (G-2) (in which E 1 represents H, F or OH; and E 2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

  本发明提供以下通式所表示的含氮融合环衍生物，或其药学上可接受的盐或前药，该衍生物在人体SGLT中表现出优异的抑制活性，并可用作预防或治疗与高血糖相关的疾病，如糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症或肥胖症的药物。其中，通式中R1代表H、可选的取代烷基、烯基等；R2代表H、卤素原子或烷基；R3和R4代表H、OH、卤素原子、可选的取代烷基等；Y代表CH或N；Q代表烷基、烯基等；环A代表芳基或杂芳基；G代表以下通式（G-1）或（G-2）所表示的基团（其中E1代表H、F或OH；E2代表H、F、甲基基团等），以及包含上述衍生物的制药组合物和制药用途。
• EP1724278B1
  申请人：——

  公开号：EP1724278B1

  公开（公告）日：2014-05-07
• US7375113B2
  申请人：——

  公开号：US7375113B2

  公开（公告）日：2008-05-20
• US7998975B2
  申请人：——

  公开号：US7998975B2

  公开（公告）日：2011-08-16